This significant stage effect leads to the differential sensitivity of classical ATN (A [CSF Ab42, or Aβ42/Ab40 ratio and amyloid PET], T [CSF p-Tau, Tau PET], and N [atomic MRI, FDG PET, and CSF total Tau]) in the diagnosis sensitivity over AD progression (Hammond et al., 2020; Sperling et al., 2011). The gene discussed is MAPT; the disease is oculocutaneous albinism type 1.